The FDA paused a controversial policy of releasing complete response letters (CRLs) that describe its rationale for rejection, according to coverage. The pause is tied to efforts to formalize the agency’s legal basis and finalize details behind proactive disclosures. The stop in new releases follows a citizen petition filed in April by an unnamed company, the coverage states. The FDA is working toward a proposed framework that would clarify how CRLs would be released in the future. For drug developers, CRL disclosure policy affects how quickly companies can interpret and act on regulatory feedback, and how much information is available to investors and stakeholders while applications remain under review.